REP1 Gene Replacement Therapy for Choroideremia

NCT02407678 | Completed Phase 2 DMC

• 1 other identifier: REGEN2015
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 2

Brief Summary

The assessment of the efficacy (with respect to preservation of visual function and retinal structure) and safety of a single subretinal injection of AAV2.REP1 in participants with a confirmed diagnosis of choroideremia, as evaluated by various functional and anatomical outcomes measured over a number of time points up to 24 months post-treatment.

Conditions

Choroideremia

Outcome Measures

Primary Outcomes (1)

• Change from baseline in best corrected visual acuity in the treated eye

  2 years

Secondary Outcomes (2)

• Change from baseline in the central visual field in the treated eye as determined by microperimetry

  2 years

• Change from baseline in the area of surviving retinal pigment epithelium in the treated eye as measured by fundus autofluorescence, compared to the untreated fellow eye (control eye) after randomisation of treatment to one eye or the other

  2 years

Study Arms (2)

Treatment

EXPERIMENTAL

Treated eye undergoes AAV-mediated REP1 gene replacement. AAV vector is delivered by subretinal injection.

Genetic: AAV-mediated REP1 gene replacement

Control

NO INTERVENTION

Untreated eye

Interventions

AAV-mediated REP1 gene replacement GENETIC

AAV vector carrying human REP1 gene is delivered into the treated eye by subretinal injection

Treatment

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Candidate is willing and able to give informed consent for participation in the study.
• Male aged 18 years or above.
• Genetic or molecular confirmed diagnosis of choroideremia (REP1 protein deficiency).
• Active disease visible clinically within the macula region.
• Best corrected visual acuity better than or equal to 6/60 (20/200; Decimal 0.1; LogMAR 1.0) in the study eye.

You may not qualify if:

• Any female, or a male aged below 18 years.
• An additional cause for sight loss (e.g. amblyopia) in the eye to be treated.
• Any other significant ocular and non-ocular disease or disorder which, in the opinion of the investigator, may put the participants at risk because of participation in the study.
• Inability to take systemic prednisolone for a period of 45 days.
• Unwillingness to use barrier contraception methods for a period of three months following gene therapy surgery.
• Participation in another research study involving an investigational product in the preceding 12 weeks.

Sponsors & Collaborators

• University of Oxford: lead
• Moorfields Eye Hospital NHS Foundation Trust: collaborator
• University College, London: collaborator

Study Sites (2)

Moorfields Eye Hospital NHS Foundation Trust

London, EC1V 2PD, United Kingdom

Location

Oxford University Hospitals NHS Foundation Trust

Oxford, OX3 9DU, United Kingdom

Location

MeSH Terms

Conditions

Choroideremia

Condition Hierarchy (Ancestors)

Eye Diseases, Hereditary; Eye Diseases; Choroid Diseases; Uveal Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Genetic Diseases, X-Linked

Study Officials

• Robert E MacLaren, MB ChB DPhil

  University of Oxford

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Masking Details: The study is designated as Open Label with no masking. However, in order to minimise bias evaluation of the treated eye and untreated fellow eye (control eye), the ophthalmic assessments (visual acuity, microperimetry, fundus autofluorescence, etc.) will be conducted by an appropriately qualified masked observer once the participant's treated eye has had time to heal after the surgical procedure and has regained its normal appearance and function.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: The decision about which eye to treat will be made on clinical grounds and will generally be the worse eye affected in cases where BCVA differs between the two eyes by 2 lines or more of ETDRS letters. The eye to be treated will be randomised in cases where the degeneration is relatively symmetrical between the two eyes, defined as: * a difference in BCVA of no more than 1 line of ETDRS letters, and * no more than 25% difference in the area of surviving RPE as measured by fundus autofluorescence. Prospective participants having non-symmetrical retinal degeneration will be allocated to the non-randomised arm. The treated eye will generally be the worse eye. Prospective participants having relatively symmetrical retinal degeneration will be allocated to the randomised arm.

Study Record Dates

• First Submitted: March 10, 2015
• First Posted: April 3, 2015
• Study Start: August 16, 2016
• Primary Completion: July 23, 2021
• Study Completion: July 23, 2021
• Last Updated: August 5, 2021

Record last verified: 2021-07

Locations

GB (2)